Secondly, we did not show experimental data to confirm the efficacy and safety of dual-targeting strategy in this study, while other companies have reported their preclinical data on bispecific ADCs targeting EGFR and MUC1 recently, which suggested the great therapeutic potential of dual-targeting drugs for cancers co-expressing EGFR and MUC1, as well as EGFR- or MUC1- expressing tumors (57, 58). Here, EGFR is linked to cancer.